Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That won't happen if we hit .09 today.
The Company has estimated that peak sales for LymPro will exceed $500 million. On June 13, 2013 , the Company entered into a Laboratory Services Agreement with Becton Dickinson for the development of LymPro using BD Biosciences Custom Technology Team
Level 2 shows almost nothing between .084 and .089
Do you think this company is only worth $40 million with this pipeline because that is the market cap.
as they are manufactured to the high standards necessary to meet the mass-scale distribution needed for LymPro to reach the over 400,000 individuals diagnosed and 5 million people living with Alzheimer's each year.
I can't either, and love it because I am one day closer to early retirement.
Mostly all buys the last 15 minutes. This bodes well for today's upward continuation.
Watch what happens when .09 is painted
MM are pulling Ask and placing on .10, so look for .09's real soon.
We blew thru to .089 Friday, and I expect light resistance until .09.
If we break thru .09 things will move up quick. IMO
New high of day! Good momentum now
As each minutes passes we are closer to the real news and everyone is well aware of that. I don't think they want to be on the sidelines when it hits the wires.
BD could also come to them with licensing agreement at the same time, which could be the the impetus to $1.00
Yep, gap closer and used it to shake some shares.
Very little resistance in the .08's
Remember how fast we went to .089 on friday.
Makes sense when you read Gerald's letter from August 6:
LymPro
Becton Dickinson ("BD") has agreed to become the development laboratory for LymPro Test ®, allowing the Company to leverage BD's team of world class scientists with deep expertise in flow-based assay execution and implementation. We are using BD's reagents in our development, as they are manufactured to the high standards necessary to meet the mass-scale distribution needed for LymPro to reach the over 400,000 individuals diagnosed and 5 million people living with Alzheimer's each year. Under the terms of the agreement, the Company retains full control and ownership over all intellectual property newly developed from all activities currently underway. We believe that leveraging BD's development expertise will significantly differentiate Amarantus' LymPro from competitors in the Alzheimer's blood biomarker space by not only reproducing high sensitivity and specificity published in peer-reviewed literature, but most importantly having the capabilities to make the assay robustly reproducible through a strong analytical performance package, as will be required to achieve deep market penetration once commercialized. We are working closely with our team of advisors to ensure that the work being conducted at BD will be of the highest standards.
Looks like the advisors think this the test is almost done and ready for commercialization!
What a nice good morning news piece! Yes, this appears to be a filler PR piece to tip the hat of Gerald's insider knowledge of BD testing results.
Good morning Lowtrade,
Thanks for your analysis of AMBS. I have struck lighting in a bottle 2 times with this stock already and am ready for a 3rd. This one has taken on huge amounts of public interest, which is why I feel the jump has occurred to this point. The trading groups that linger amongst these boards probably helped the increase here too.
There is much news looming in the near horizon that I expect continuation through .09 level real soon. News does trump all right?
I know you are the dark side master, especially when it comes to trading manipulation for/from funding deals. It is known that AMBS needs additional funding to continue advancing some of their pipeline through different phases of trials. Wouldn't the need for additional funding still cause major manipulation to occur?
Furthermore, if the previous conversion from Dominion Capital has already been sold, and sold for a very nice quick profit. Wouldn't it be likely they could re-introduce a new investment stake?
Ophthalmology: MANF’s Orphan Strategy Coming into Focus in Retinitis Pigmentosa
MANF continues to perform on so many different levels for Amarantus. While the recent focus has been on the Company’s nearer-term product candidate LymPro, it is critically important to remember the vast potential of our MANF program. What I find most remarkable about the sheer breadth of the Company’s lead therapeutic program is that, in the end, all of its potential applications to treat diseases in various organs throughout the body, including the brain, heart, and most recently the eye, are based on the exact same fundamental biological mechanism: mitigating apoptosis.
Retinitis Pigmentosa (RP) is a chronic progressive degenerative disorder of the eye that is characterized by the death of photoreceptor cones and rods in the retinal pigment epithelium (RPE). It is a genetic disease that affects roughly 100,000 people in the United States, 100,000 people in Europe and 50,000 people in Japan. Due to its relatively small patient population, RP qualifies as an orphan indication which provides a number of financial incentives for development of MANF in this indication. Further, there is a very significant unmet medical need as few therapies effectively treat this population of patients, leaving most legally blind before they reach the age of 50. Moreover, delivery of MANF directly into the eye is far simpler than Convection Enhanced Delivery in Parkinson’s, or systemic delivery in Ischemic Heart Disease. Together, the components of a smaller patient population, a significant unmet medical and a local delivery need may provide an ideal opportunity for the rapid clinical development of MANF that could lead to commercialization years ahead of larger indications for MANF.
We believe RP is just the beginning of the MANF story in ophthalmology. Other neurotrophic factors have begun to show promise in many diseases in the area and the data announced earlier this week scientifically supports development in many therapeutic indications beyond RP in ophthalmology, including Dry Age-Related Macular Degeneration (Dry AMD). Dry AMD affects approximately 15 million people in the United States. 14%-24% of the U.S. population age 65-74 years and 35% of people aged 75 years or older have the disease[1]. Currently, there are no available disease-modifying treatments for Dry AMD, making the opportunity for MANF so attractive. MANF’s development in RP may accelerate the pathway for it to reach the significantly larger Dry AMD patient population by proving cone and rod protection in humans in the smaller RP population first.
Ophthalmology has taken on significantly greater interest as of late from major players in the biopharmaceutical industry: Pfizer Inc. (PFE), Allergan Inc. (AGN), Alcon Inc. (ACL), Novartis AG (NVS), Merck & co. Inc. (MRK) and Roche (RHHBY) cover approximately 70% of the $10 billion market. The primary reason why the ophthalmology market is currently so small is very simple: very few effective disease-modifying treatments exist. Interestingly, the FDA notes that only 21 new drugs were approved in the last 10 years, suggesting a significant lack of breakthrough biology in this space, as evidenced by these companies’ thin ophthalmology pipelines. What’s more, these companies have primarily added drug candidates to their pipelines through in-licensure and strategic transactions, making the opportunity even more appealing for Amarantus. There is no question that the medical outcome of new, truly disease-modifying treatments in the area will have a meaningful impact on patients’ lives; being able to see versus being blind is a massive improvement in quality of life that would undoubtedly be highly coveted by patients, caregivers and physicians.
As we continue our pursuit of identifying a variety of orphan indications for MANF, this first success is a major milestone. When data becomes available in the coming weeks on different applications, we will begin to spend some time reprioritizing our MANF pipeline to ensure that we are maximizing shareholder value, while simultaneously ensuring that we are expeditiously moving MANF forward in the various indications where MANF has shown benefit pre-clinically. We intend to rely heavily on not-for-profit funding for certain indications in order to minimize shareholder dilution while maximizing patient benefit as we move MANF forward. The economies of scale created by having a single therapeutic candidate treat multiple diseases cannot be overstated, as development milestones in one area support further development in the others. The Company’s orphan drug strategy outlined in November of 2012 is beginning to bear fruit and we intend to pursue orphan diseases aggressively as we see this as the most effective and expeditious route to getting MANF to patients.
A prime example of a successful orphan strategy is Genzyme, which was acquired by Sanofi Aventis (SNY) in 2011 for $20.1B. Another example of a successful orphan strategy is FerroKin Biosciences, which was acquired by Shire (SHPG) for $325M in early 2012 with only $27M in paid-in-capital and a virtual staff of 7 employees. In 2011, Alexion Pharmaceuticals (ALXN) reported $783M in revenue based on sales of its only product Soliris, a drug that treats a population of approximately 10,000 patients in the US and Western Europe.
We have taken a very important step forward in our MANF program and strategy and are looking forward to updating shareholders on further developments in the weeks and months ahead.
Thank you for taking the time to read this blog.
Gerald Commissiong
President & CEO
Amarantus Engages BD Biosciences for Development of Alzheimer’s Diagnostic
SUNNYVALE, Calif.-- Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today announced it has signed a laboratory services agreement with BD Biosciences, a segment of BD (Becton, Dickinson and Company) , a leading global medical technology company, under which BD’s BD Biosciences Custom Technology Team will perform sample analysis on Amarantus’ LymPro Test® for Alzheimer’s disease. Financial terms were not disclosed.
“The LymPro Test is potentially the first available blood test for Alzheimer’s disease,” said Gerald E. Commissiong, President & CEO of Amarantus. “With this agreement, we expect to have initial data available in the third quarter of 2013, and now have the capabilities required to place LymPro on a path for commercialization in 2014.”
Amarantus and BD Biosciences will be focused on verifying the analytical performance characteristics of LymPro necessary to achieve reproducibility of the assay. Over time, Amarantus expects to execute multiple clinical studies and begin worldwide sales of LymPro as the first diagnostic blood test for Alzheimer’s disease.
AMBS is no POS unless you are short. News expected any day from BD that could verify LymPro, which will likely take this to .20-.30 imo. Then if BD signs licensing deal, which is very likely, then $1.00
Oh, and Gerald is speaking at a conference he was personally invited to in Europe next week. More news to come...stay tuned my friend.
I think everyone will be telling their friend about AMBS over the weekend. Could have a large increase of shareholder upon our return next week.
Wow, they are maintaining a huge spread.
MM got caught off guard there and now they are trying to widen the spread to keep from getting to .09 too fast. Looks like they want to buy more before we break .09
If we break .09 then .10 will be a quick flash
Level 2 does not show much resistance up to .10
Ophthalmology: MANF’s Orphan Strategy Coming into Focus in Retinitis Pigmentosa
MANF continues to perform on so many different levels for Amarantus. While the recent focus has been on the Company’s nearer-term product candidate LymPro, it is critically important to remember the vast potential of our MANF program. What I find most remarkable about the sheer breadth of the Company’s lead therapeutic program is that, in the end, all of its potential applications to treat diseases in various organs throughout the body, including the brain, heart, and most recently the eye, are based on the exact same fundamental biological mechanism: mitigating apoptosis.
Retinitis Pigmentosa (RP) is a chronic progressive degenerative disorder of the eye that is characterized by the death of photoreceptor cones and rods in the retinal pigment epithelium (RPE). It is a genetic disease that affects roughly 100,000 people in the United States, 100,000 people in Europe and 50,000 people in Japan. Due to its relatively small patient population, RP qualifies as an orphan indication which provides a number of financial incentives for development of MANF in this indication. Further, there is a very significant unmet medical need as few therapies effectively treat this population of patients, leaving most legally blind before they reach the age of 50. Moreover, delivery of MANF directly into the eye is far simpler than Convection Enhanced Delivery in Parkinson’s, or systemic delivery in Ischemic Heart Disease. Together, the components of a smaller patient population, a significant unmet medical and a local delivery need may provide an ideal opportunity for the rapid clinical development of MANF that could lead to commercialization years ahead of larger indications for MANF.
We believe RP is just the beginning of the MANF story in ophthalmology. Other neurotrophic factors have begun to show promise in many diseases in the area and the data announced earlier this week scientifically supports development in many therapeutic indications beyond RP in ophthalmology, including Dry Age-Related Macular Degeneration (Dry AMD). Dry AMD affects approximately 15 million people in the United States. 14%-24% of the U.S. population age 65-74 years and 35% of people aged 75 years or older have the disease[1]. Currently, there are no available disease-modifying treatments for Dry AMD, making the opportunity for MANF so attractive. MANF’s development in RP may accelerate the pathway for it to reach the significantly larger Dry AMD patient population by proving cone and rod protection in humans in the smaller RP population first.
Ophthalmology has taken on significantly greater interest as of late from major players in the biopharmaceutical industry: Pfizer Inc. (PFE), Allergan Inc. (AGN), Alcon Inc. (ACL), Novartis AG (NVS), Merck & co. Inc. (MRK) and Roche (RHHBY) cover approximately 70% of the $10 billion market. The primary reason why the ophthalmology market is currently so small is very simple: very few effective disease-modifying treatments exist. Interestingly, the FDA notes that only 21 new drugs were approved in the last 10 years, suggesting a significant lack of breakthrough biology in this space, as evidenced by these companies’ thin ophthalmology pipelines. What’s more, these companies have primarily added drug candidates to their pipelines through in-licensure and strategic transactions, making the opportunity even more appealing for Amarantus. There is no question that the medical outcome of new, truly disease-modifying treatments in the area will have a meaningful impact on patients’ lives; being able to see versus being blind is a massive improvement in quality of life that would undoubtedly be highly coveted by patients, caregivers and physicians.
As we continue our pursuit of identifying a variety of orphan indications for MANF, this first success is a major milestone. When data becomes available in the coming weeks on different applications, we will begin to spend some time reprioritizing our MANF pipeline to ensure that we are maximizing shareholder value, while simultaneously ensuring that we are expeditiously moving MANF forward in the various indications where MANF has shown benefit pre-clinically. We intend to rely heavily on not-for-profit funding for certain indications in order to minimize shareholder dilution while maximizing patient benefit as we move MANF forward. The economies of scale created by having a single therapeutic candidate treat multiple diseases cannot be overstated, as development milestones in one area support further development in the others. The Company’s orphan drug strategy outlined in November of 2012 is beginning to bear fruit and we intend to pursue orphan diseases aggressively as we see this as the most effective and expeditious route to getting MANF to patients.
A prime example of a successful orphan strategy is Genzyme, which was acquired by Sanofi Aventis (SNY) in 2011 for $20.1B. Another example of a successful orphan strategy is FerroKin Biosciences, which was acquired by Shire (SHPG) for $325M in early 2012 with only $27M in paid-in-capital and a virtual staff of 7 employees. In 2011, Alexion Pharmaceuticals (ALXN) reported $783M in revenue based on sales of its only product Soliris, a drug that treats a population of approximately 10,000 patients in the US and Western Europe.
We have taken a very important step forward in our MANF program and strategy and are looking forward to updating shareholders on further developments in the weeks and months ahead.
Thank you for taking the time to read this blog.
Gerald Commissiong
President & CEO
Amarantus Engages BD Biosciences for Development of Alzheimer’s Diagnostic
SUNNYVALE, Calif.-- Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today announced it has signed a laboratory services agreement with BD Biosciences, a segment of BD (Becton, Dickinson and Company) , a leading global medical technology company, under which BD’s BD Biosciences Custom Technology Team will perform sample analysis on Amarantus’ LymPro Test® for Alzheimer’s disease. Financial terms were not disclosed.
“The LymPro Test is potentially the first available blood test for Alzheimer’s disease,” said Gerald E. Commissiong, President & CEO of Amarantus. “With this agreement, we expect to have initial data available in the third quarter of 2013, and now have the capabilities required to place LymPro on a path for commercialization in 2014.”
Amarantus and BD Biosciences will be focused on verifying the analytical performance characteristics of LymPro necessary to achieve reproducibility of the assay. Over time, Amarantus expects to execute multiple clinical studies and begin worldwide sales of LymPro as the first diagnostic blood test for Alzheimer’s disease.
Glad to see we hit a new high of day while I was out for lunch. Now let's break through .08's
Big sell orders are getting pulled again, so watch as we go up from here.
13 million shared traded before 11:30AM
That is a good sign of what is to come next week.
Agree, there is a lot of news to be disseminated in the immediate future. The risk v. reward is way better than any vegas odds.
If you think this week was a good week, wait until next week. I don't know many who will want to be on sidelines over the weekend with the BD news due any day.
Just hit 8 million traded and only 11:00 AM
This will hit a lot of traders radars and only send this higher. If they read about the company they may even keep some for the real news!
Of course...News trumps all and anticipation establishes a pent up demand. Can't wait.
Next resistance will be .085 - .09, so look for .07's to be gone soon!
Watch everyone chase this into the mid .07's
Boom! Here we go for the next leg up.
Something good is happening on the surface. PR's are proof!
Get ready...NITE just bumped support at .066 for 300,000
Market Makers are trying to widen the gap to slow upward movement.
Are you seeing all the buys v. very few sells...good sign for explosion in upward momentum